RNA-seq of PBX1 knock-down or overexpressing cell lines
The whole study comprises of two patient cohorts. Screening cohort: 40 patients of Germany; validation cohort: 40 patients from Asia. Further, bile duct and CCA cell lines have been analyzed. This dataset contains 44 samples derived from RNA-sequencing data of bile duct and CCA cell lines. Data was generated on Illumina NovaSeq 6000 device in paired-end mode and is stored in compressed FASTQ file format.
- 44 samples
- DAC: EGAC00001003403
- Technology: Illumina NovaSeq 6000
The data is available for non-commercial use only. Data security standards have to be followed as described under “policy”.
1. The User and the User Institution(s) agree to use the Data only for the advancement of medical research. And not to use the data for the creation of products for sale or for any commercial purpose. 2. The User and the User Institution(s) agree to use the Data for no other purpose than the approved purpose and project described in the collaboration proposal; use of the Data for a other/new purpose or project will require a new application and approval. 3. The User and the User Institution(s) agree to preserve, at all times, the confidentiality of the information and Data set. In particular, they undertake not to use, or attempt to use the Data set to compromise or otherwise infringe the confidentiality of information on Research Participants. 4. The User and the User Institution(s) agree to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. The User and the User Institution(s) agree not to pursue any research with the goal to identify Research Participants and not to link or combine the Data set provided under this agreement to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User and the User Institution(s), or is freely available without restriction. 5. The User and the User Institution(s) agree not to transfer or disclose the Data set, in whole or part, or any material derived from the Data set, to anyone not listed in this application form, except as necessary for data safety monitoring, national audits or program management. Should the User or the User Institution(s) wish to share the Data set with an External Collaborator, the External Collaborator must complete a separate Collaborator's Form for Access to the Data set. 6. The User and the User Institution(s) accept that the Data is protected by and subject to national and international laws, including but not limited to the General Data Protection Regulation (GDPR) and that the User and the User Institution are responsible for ensuring compliance with any such applicable law. User Institutions located outside the EU/EEA (European Economic Area) are requested to additionally enter into the Standard Contractual Clauses for the Transfer of Personal Data to Third Countries. The Consortium Data Access Committee reserves the right to request and inspect data security and management documentation to ensure the adequacy of data protection measures in countries that have no national laws comparable to that which pertain in the EU. 7. The User and the User Institution(s) accept that Data producers, depositors or copyright holders, or the funders of the Data set or any part of the Data set supplied: a) bear no legal responsibility for the accuracy or comprehensiveness of the Data set; b) accept no liability for indirect, consequential, or incidental, damages or losses arising from use of the Data set, or from the unavailability of, interruption in Data set access for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data set, over and above that published by the Consortium. 8. The User and the User Institution(s) agree not to make intellectual property claims on the Data set (including somatic mutations) and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of the Data set, or conclusion drawn directly from the Data set. 9. The User and the User Institution(s) can elect to perform further research that would add intellectual and resource capital to the data set and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User and the User Institution(s) agree to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health’s, Best Practices for the Licensing of Genomic Inventions or a similar national guideline that is in conformity with the OECD, Guidelines for the Licensing of the Genetic Inventions: OECD (2006), OECD Guidelines for the Licensing of Genetic Inventions, OECD Publishing, Paris, https://doi.org/10.1787/9789264018273-en-fr.. 10. The User shall be free to publish the results of the research using the Data for the approved purpose. The User agrees to acknowledge in any such publication that the research makes use of Data generated by the Data Producer. 11. The User and the User Institution(s) agree to destroy any Data held, once it is no longer used for the indicated project described in this application form unless obligated to retain the data set for archival purposes in conformity with national audits or legal requirements. 12. The User and the User Institution(s) will notify the Data Access Committee as soon as they become aware of a breach of the terms or conditions of this agreement. 13. The User and the User Institution(s) agree that they will submit a final report to the Data Access Committee sixty (60) days on completion of the agreed purpose. The Data Access Committee agrees to treat the report and all information, data, results, and conclusions contained within such report as confidential information belonging to the User Institution. 14. If requested, the User and the User Institution(s) will allow data security and management documentation and corresponding physical installations to be inspected to verify that they are complying with the terms of this Data Access Agreement. 15. This Agreement shall be effective as of the date of the last party to sign below (“Effective Date”) and shall terminate three (3) years after the Effective Date, unless terminated sooner pursuant to Section 16 below. 16. The User and the User Institution(s) accept that this agreement may terminate immediately upon any breach of this agreement from the User and the User Institution(s). Either Party may terminate this Agreement upon thirty (30) days written notice for any reason. 17. In case of section 15 or 16 the User and the User Institution(s) will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User and the User Institution(s) from retaining the data set for archival purpose in conformity with national audits or legal requirements. 18. The following Sections of this Agreement shall survive its expiration or termination: Sections 1-11, 13-15, 19. 19. The User and the User Institution(s) agree to distribute a copy of this agreement and explain its content to any person mentioned in this application form. 20. This agreement shall be construed, interpreted and governed by the laws of Germany and shall be subject to the non-exclusive jurisdiction of the German courts.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS00001007525 | Cancer Genomics |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.